Grandpa and Nonny (Myself) Print

These paintings are a testament to the perseverance of his hard work and determination. Dr Hensley is an international known innovator, visionary, entrepreneur, scientific with a global footprint. He has been featured in USA Today, Time Magazine and has appeared on CNBC Squawk Box Asia. Dr Hensley, discover and development ZICAM cold and remedy (considering by many “the cure for the common Cold”), founded ZICAM LLC and went on to market this iconic American brand. Dr Hensley has written two novels, COLD WARS and FLU WARS. Cold Wars is the story of his discovery and marketing of ZICAM. FLU WARS is Dr Hensley account of his scientific and political experience with emerging viral disease such SARS and Avian influenza. Pharmaceuticals In 1997, Hensley invented and developed Zicam cold remedy, one of the most successful OTC remedies for the common cold on the market. Hensley also invented and developed the underlying nasal delivery system used in the Zicam products. As a means to fast track Zicam to the marketplace, Hensley and his partners co-founded Gel Tech, LLC. (now Zicam, LLC.), with Gum Tech International (now Matrixx Initiatives, Inc.).. Upon his return to California in 2005, PRB Pharmaceuticals acquired NeoDiagnostics, Inc. and Hensley refined the technology that emerged from his "Taiwan and Hong Kong days" which ultimately led to the development of a suite of broad spectrum anti-viral products. In 2006, Hensley licensed the anti-viral products to Pacific BioPharmaceuticals, which as part of the licensing deal, merged with Abattis Biologix Corporation making Hensley a major shareholder. In 2007, Hensley founded Nasal Therapeutics, Inc. to develop and market nasal spray technologies and products. That same year, Nasal Therapeutics, Inc. entered into a licensing agreement with Therabiogen, Inc., which allowed them the exclusive right to manufacture, market and sell two nasal therapeutic nasal sprays, Theramax Cold and Flu Relief and Theramax Allergy Relief. As a result of the deal, Hensley became Therabiogen's largest shareholder. Subsequently, Hensley developed a new platform technology based on his theory of altered functioning of EAA transport proteins in neurodegenerative diseases. From this platform, Hensley developed a series of therapies including one for the treatment for migraine headaches. Hensley subsequently formed Migranade, Inc. to further develop the migraine treatment for the market.